Sanford C. Bernstein set a GBX 1,580 ($22.15) price target on GlaxoSmithKline (LON:GSK) in a report published on Wednesday morning. The firm currently has a neutral rating on the stock.

Several other brokerages also recently commented on GSK. Deutsche Bank increased their price target on GlaxoSmithKline from GBX 1,380 ($19.35) to GBX 1,440 ($20.19) and gave the company a hold rating in a report on Thursday, January 11th. set a GBX 1,925 ($26.99) price target on GlaxoSmithKline and gave the company a buy rating in a report on Thursday, October 26th. Morgan Stanley lowered their price target on GlaxoSmithKline from GBX 1,450 ($20.33) to GBX 1,400 ($19.63) and set an underweight rating on the stock in a report on Friday, December 1st. Berenberg Bank lowered their price target on GlaxoSmithKline from GBX 1,835 ($25.73) to GBX 1,760 ($24.68) and set a buy rating on the stock in a report on Thursday, November 2nd. Finally, Goldman Sachs Group set a GBX 1,775 ($24.89) price target on GlaxoSmithKline and gave the company a buy rating in a report on Friday, October 27th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of GBX 1,540.68 ($21.60).

GlaxoSmithKline (LON GSK) opened at GBX 1,316.20 ($18.45) on Wednesday. GlaxoSmithKline has a twelve month low of GBX 1,235.20 ($17.32) and a twelve month high of GBX 1,724.50 ($24.18). The company has a market capitalization of $65,780.00 and a P/E ratio of 4,245.81.

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The company reported GBX 111.80 ($1.57) EPS for the quarter, beating the consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01). GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. The company had revenue of GBX 763.90 billion for the quarter.

In other GlaxoSmithKline news, insider Sir Roy Anderson purchased 562 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were purchased at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of GlaxoSmithKline stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). Insiders have acquired 581 shares of company stock worth $743,284 in the last quarter.

WARNING: “GlaxoSmithKline (GSK) Given a GBX 1,580 Price Target by Sanford C. Bernstein Analysts” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2018/02/08/glaxosmithkline-gsk-given-a-gbx-1580-price-target-by-sanford-c-bernstein-analysts.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.